Haris Ali, MD, discusses the results of a study evaluating peri-transplant ruxolitinib in patients with myelofibrosis.
Haris Ali, MD, a hematologist/oncologist and associate clinical professor, Department of Hematology & Hematopoietic Cell Transplantation at City of Hope Comprehensive Cancer Center, discusses the results of a study evaluating peri-transplant ruxolitinib in patients with myelofibrosis.
The pilot study aimed to assess the safety and efficacy of the per-transplant ruxolitinib strategy. In terms of safe, Ali says that strategy was well-tolerated, with most of the toxicities being grade 1 in severity. Few patients experienced grade 2 or 3 toxicities, which included renal failure and cardiac arrest in 2 patients. These events were not related to ruxolitinib, Ali explains.
Results also showed that the incidence of high-grade graft-versus-host disease was low in this study. These findings confirm the original hypothesis of the study.
Ruxolitinib Offers Durable Hematocrit Control, Low Thrombosis Risk in PV
May 30th 2024In an interview with Targeted Oncology, Aleksander L. Chojecki, MD, discussed findings from his research on hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib.
Read More
Breast Cancer Survivors Find Success With Pregnancy After Treatment
May 24th 2024A study offers promising news for young women with early-stage breast cancer who want to have children after treatment, showing that 73% of breast cancer survivors who attempted pregnancy were successful.
Read More